Previous 10 | Next 10 |
Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...
NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Plug Power, Inc. (NASDAQ:...
Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Alexion Pharmaceuticals ( ALXN ) is a name which surfaced on my radar last year as I was looking across the biotechnology sector for bargains. Unfortunately, Alexion did not present real value in my eyes although I noted that appeal was on the increase. Shares traded at $115 at the time ...
Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
"A cynic is a man who, when he smells flowers, looks around for a coffin." - H.L. Mencken Stocks ended January on a high note with the major indices up just under one and half percent last week. It was the best start to a New Year since 1987 for investors after a dismal fourth quarter. T...
Alexion Pharmaceuticals, Inc. (ALXN) Q4 2018 Earnings Conference Call February 04, 2019, 08:00 ET Company Participants Susan Altschuller - VP, IR Ludwig Hantson - CEO & Director Paul Clancy - EVP & CFO John Orloff - EVP and Head, Research & Development Brian Goff ...
The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2018 Q4 earnings Read more ...
Alexion Pharmaceuticals ( ALXN +2.7% ) Q4 results : Revenues: $1,128.8M (+24.1%); SOLIRIS: $976.7M (+23.3%); STRENSIQ: $126.1M (+31.9%); KANUMA: $25.7M (+17.4%). More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Re...
Alexion Pharmaceuticals (NASDAQ: ALXN ): Q4 Non-GAAP EPS of $2.14 beats by $0.32 ; GAAP EPS of -$0.20 beats by $0.23 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Alexion Pharmaceuticals Inc. Company Name:
ALXN Stock Symbol:
NASDAQ Market:
Alexion Pharmaceuticals Inc. Website:
AstraZeneca (NASDAQ: AZN) hopes to soon close its planned acquisition of Alexion Pharmaceuticals (NASDAQ: ALXN) . The only hurdle left to jump is obtaining approval from United Kingdom regulators. In this Motley Fool Live video recorded on July 7 , Motley Fool contri...
This week, pharma and biotech giant AstraZeneca (NASDAQ: AZN) cleared its final hurdle in the proposed acquisition of orphan drug pharma company Alexion Pharmaceuticals (NASDAQ: ALXN) when it announced that the deal had received clearance from the United Kingdom's Compet...